Darweesh SK, et al. - Researchers evaluated nucleos(t)ide analogs (NUCs) prophylaxis (±HBIG), in terms of efficacy and safety, against hepatitis B virus (HBV) recurrence after liver transplantation (LTx). In this retrospective cohort-longitudinal study of 44 HBV-related post-LTx patients on anti-HBV prophylactic therapy, the entecavir (ETV)-based (n=34, 30 males) and the other NUC-based (n=10, 7 males) groups±HBIG were analyzed. Outcomes suggest the efficacy and safety of ETV and other NUCs as long-term prophylaxis of HBV recurrence after LTx, leading to a good graft function. In a minority of patients, HBsAg temporally reappeared, where all showed HBsAb seroconversion without detectable HBV-DNA or clinical hepatitis.